Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02795676
Other study ID # PB-102-F20
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2016
Est. completion date July 2022

Study information

Verified date September 2023
Source Protalix
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients who had been treated for approximately 1 year with agalsidase beta and who had been on a stable dose of that product for at least 6 months were randomized in a 2:1 ratio to either switch to PRX-102 or to continue treatment with agalsidase beta. Both treatments were delivered by intravenous infusions every two weeks, at a dosage of 1 mg/kg.


Description:

This was a randomized, double-blind, active control study examining the safety and efficacy of pegunigalsidase alfa (PRX-102) in Fabry disease patients with impaired renal function. Participants had to have been taking the licensed ERT drug agalsidase beta (Fabrazyme®) for at least 1 year prior to study entry, and to have been on a stable dose of that product for at least the last 6 months. Since the disease expresses itself differently in males and females, gender could have an impact on the therapeutic effect; thus, there was additionally a requirement that no more than 50% of the patients could be female. Following screening, eligible patients were randomized in a 2:1 ratio to either switch to PRX-102 or continue treatment with agalsidase beta, with randomization stratified according to whether the urine protein-to-creatinine ratio (UPCR), a measure of kidney function, was above or below a specified threshold. Both products were administered as an intravenous infusion every 2 weeks, at a dosage of 1 mg/kg, for up to 24 months. Both patients and study staff were blinded as to which treatment was being given. Patients who completed the study were invited to continue in a long-term open-label extension study, PB-102-F60, in which all participants would receive PRX-102 1 mg/kg every 2 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date July 2022
Est. primary completion date October 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Symptomatic adult Fabry disease patients, age 18-60 years 1. Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than 30% mean normal levels and one or more of the characteristic features of Fabry disease i. neuropathic pain ii. cornea verticillata iii. clustered angiokeratoma 2. Females: a. historical genetic test results consistent with Fabry pathogenic mutation and one or more of the described characteristic features of Fabry disease: i. neuropathic pain ii. cornea verticillata iii. clustered angiokeratoma b. or in the case of novel mutations a first degree male family member with Fabry disease with the same mutation, and one or more of the characteristic features of Fabry disease i. neuropathic pain ii. cornea verticillata iii. clustered angiokeratoma - Screening eGFR by CKD-EPI equation 40 to 120 mL/min/1.73 m² - Linear negative slope of eGFR based on at least 3 serum creatinine values over approximately 1 year (range of 9 to 18 months, including the value obtained at the screening visit) of = 2 mL/min/1.73 m²/year - Treatment with a dose of 1 mg/kg agalsidase beta per infusion every 2 weeks for at least one year and at least 80% of 13 (10.4) mg/kg total dose over the last 6 months. - Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically accepted method of contraception, not including the rhythm method. Exclusion Criteria: - History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase beta - Known non-pathogenic Fabry mutations - History of renal dialysis or transplantation - History of acute kidney injury in the 12 months prior to screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive nephropathy) - Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated or dose changed in the 4 weeks prior to screening - Patient with a screening eGFR value between 91-120 mL/min/1.73 m², having an historical eGFR value higher than 120 mL/min/1.73 m² (during 9 to 18 months before screening) - Urine protein to creatinine ratio (UPCR) > 0.5 g/g and not treated with an ACE inhibitor or ARB - Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period before randomization - Congestive heart failure NYHA Class IV - Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before randomization - Known history of hypersensitivity to Gadolinium contrast agent that is not managed by the use of pre-medication - Female subjects who are pregnant, planning to become pregnant during the study, or are breastfeeding - Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient's compliance with the requirements of the study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
PRX-102 (pegunigalsidase alfa)
PRX-102 1 mg/kg every 2 weeks
agalsidase beta
agalsidase beta 1 mg/kg every 2 weeks

Locations

Country Name City State
Czechia Vseobecna fakultni nemocnice v Praze Prague Czech Republic
Finland Turku University Central Hospital Turku
France Hôpital Raymond Poincaré Paris
Hungary Semmelweis Egyetem Budapest
Italy Azienda Ospedaliera Universitaria "Federico II" Napoli
Netherlands Academisch Medisch Centrum Amsterdam
Norway Haukeland University Hospital Klinisk Forskningspost Bergen
Slovenia General Hospital Slovenj Gradec Slovenj Gradec
Spain Hospital de Dia Quiron Zaragoza Zaragoza
Switzerland Klinik und Poliklinik für Innere Medizin UniversitätsSpital Zürich Zürich
United Kingdom Addenbrooke's Hospital Cambridge
United Kingdom Institute of Metabolism and Systems Research Edgbaston Birmingham
United Kingdom The Royal Free Hospital London
United Kingdom Salford Royal NHS Foundation Trust Salford
United States Emory University School of Medicine Atlanta Georgia
United States UAB Medicine Birmingham Alabama
United States Massachusetts General Hospital Boston Massachusetts
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Institute of Metabolic Disease, Baylor Healthcare Dallas Texas
United States Renal Disease Research Institute, LLC - Dallas Dallas Texas
United States O+O Alpan LLC Fairfax Virginia
United States Infusion Associates Grand Rapids Michigan
United States University of Iowa Hosptials and Clinics Iowa City Iowa
United States Medical College of Wisconsin Milwaukee Wisconsin
United States University of California Irvine Center Orange California
United States Phoenix Children's Hospital Phoenix Arizona
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Eccles Primary Children's Outpatient Services Building Salt Lake City Utah
United States University of California San Diego San Diego California

Sponsors (2)

Lead Sponsor Collaborator
Protalix Chiesi Farmaceutici S.p.A.

Countries where clinical trial is conducted

United States,  Czechia,  Finland,  France,  Hungary,  Italy,  Netherlands,  Norway,  Slovenia,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) The individual annualized mean change (slope) in eGFR (mL/min/1.73 m^2/year) is an estimate of the individual patient's annualized change in eGFR, which is derived from the eGFR assessments over time, for up to 24 months.
The individual annualized mean change (slope) in eGFR is estimated for each patient with at least 4 eGFR observations. For patients with fewer than 4 eGFR observations, the slope will be missing.
24 months
Secondary Estimated Glomerular Filtration Rate (eGFR) eGFR was calculated based on measured serum creatinine levels according to the CKD-EPI formula. The median values obtained at baseline and at Month 24 are reported.
The change in eGFR from baseline measurement prior to first infusion to last measurement at Month 24 was summarized using descriptive statistics.
The change was calculated for each subject and the reported value is the median (full range) of these changes.
Baseline and Month 24
Secondary Plasma Lyso-Gb3 Globotriaosylsphingosine (lyso-Gb3) is a Fabry disease-specific biomarker measured in the plasma. The median concentrations obtained at baseline and at Month 24, and the change from baseline to Month 24 in median concentration, are reported.
The change in Lyso-Gb3 from baseline measurement prior to first infusion to last measurement at Month 24 was summarized using descriptive statistics.
The change was calculated for each subject and the reported value is the median (full range) of these changes.
Baseline and Month 24
Secondary Short Form Brief Pain Inventory (BPI) The Short Form Brief Pain Inventory ( BPI) questioner is self-completed by patients regarding pain severity and interference.
Descriptive statistics summarize the findings for the change from baseline at Week 104 for "Pain at Its Worst in Last 24 Hours".
The severity of various aspects of pain scored on a scale of 0 to 10 ( no pain / pain as bad as you can imagine).
The change in BPI from baseline measurement prior to first infusion to the last measurement at Month 24 was summarized using descriptive statistics.
The change was calculated for each subject and the reported value is the mean (Standard Error) of these changes.
Baseline and Month 24
Secondary Mainz Severity Score Index (MSSI) The Mainz Severity Score Index (MSSI) is an instrument that is specifically designed to measure the severity of Fabry disease signs/symptoms and to monitor the clinical course of the disease. The MSSI is administered by the investigator, and yields scores for general, neurological, cardiovascular, renal, and overall assessments. The overall score range from 0 to 76. An overall score of less than 20 points is considered mild signs and symptoms of Fabry disease, 20 to 40 is considered moderate, and greater than 40 is considered severe.
The change in overall MSSI score from baseline measurement prior to first infusion to the last measurement at Month 24 was summarized using descriptive statistics.
The change was calculated for each subject and the reported value is the mean (Standard Error) of these changes.
Baseline and Month 24
Secondary Urine Protein/Creatinine Ratio (UPCR) The UPCR provides an estimate of protein excretion in urine, and is used as an indicator of the extent of chronic kidney disease. It was classified into three categories: 1) UPCR = 0.5 gr/gr, 2) 0.5 gr/gr < UPCR < 1 gr/gr, 3) 1 gr/gr = UPCR. The results are presented as the percentage of patients (%) in each category at baseline and Month 24.
There are no statistical analyses for this endpoint.
Baseline and Month 24
Secondary Left Ventricular Mass Index With Hypertrophy at Baseline Left Ventricular Mass Index (LVMI) based on cardiac MRI for patients with hypertrophy at baseline (for males, hypertrophy is above 91 g/m^2 and for females, above 77 g/m^2).
The change in LVMI from baseline measurement prior to first infusion to the last measurement at Month 24 was summarized using descriptive statistics.
The change was calculated for each subject and the reported value is the median (full range) of these changes.
Baseline and Month 24
Secondary Left Ventricular Mass Index Without Hypertrophy at Baseline Left Ventricular Mass Index (LVMI) based on cardiac MRI for patients without hypertrophy at baseline (for males, hypertrophy is above 91 g/m^2 and for females, above 77 g/m^2).
The change in LVMI from baseline measurement prior to first infusion to the last measurement at Month 24 was summarized using descriptive statistics.
The change was calculated for each subject and the reported value is the median (full range) of these changes.
Baseline and Month 24
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Completed NCT04455230 - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 Phase 1/Phase 2
Completed NCT01218659 - Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease Phase 3
Completed NCT00304512 - A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease Phase 2
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT03500094 - Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) Phase 3
Withdrawn NCT04143958 - To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease Phase 4
Recruiting NCT02994303 - Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy N/A
Completed NCT01947634 - Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study. N/A
Recruiting NCT01695161 - Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer. N/A
Completed NCT01853852 - A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects Phase 1
Completed NCT00701415 - A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Phase 3
Completed NCT00068107 - Dosing Study of Replagal in Patients With Fabry Disease Phase 2
Completed NCT01997489 - Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Phase 4
Recruiting NCT06007768 - Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
Recruiting NCT05698901 - Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Active, not recruiting NCT03305250 - Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease N/A
Terminated NCT00526071 - Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study Phase 2
Active, not recruiting NCT03566017 - Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease Phase 3
Recruiting NCT06065605 - Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease